Tetrabenazine

Evidence Level: L5

Predicted Indications: 10

Tetrabenazine

Pharmacist Assessment Report

Tetrabenazine: From Huntington Disease to polycystic kidney disease 3 with or without polycystic liver disease

One-Sentence Summary

Tetrabenazine is a VMAT2 inhibitor originally used for movement disorders associated with Huntington disease and related conditions. The TxGNN model predicts it may be effective for polycystic kidney disease 3 with or without polycystic liver disease, but there are currently 0 clinical trials and 0 publications supporting this prediction. It is a model-only prediction with no biological rationale identified.

Quick Overview

Item	Content
Original Indication	Huntington disease and related conditions (Huntington disease-like syndromes, juvenile Huntington disease, McLeod neuroacanthocytosis syndrome). The ARTG entry in the data compiled for this report has no indication text.
Predicted New Indication	Polycystic kidney disease 3 with or without polycystic liver disease
TxGNN Prediction Score	0.9990
Evidence Level	L5
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, tetrabenazine is a reversible VMAT2 inhibitor that depletes presynaptic monoamines in the central nervous system. Its efficacy in hyperkinetic movement disorders such as Huntington disease is the basis of its original use.

No mechanistic link to the predicted indication has been established. Polycystic kidney and liver disease (for example, GANAB/PRKCSH-related forms) arises from defects in endoplasmic reticulum protein processing and cyst formation, which are not known to involve monoamine handling. The high TxGNN score appears to reflect network-based associations rather than a biological rationale, and should be treated as a hypothesis only.

The other top-ranked predictions (for example renal-hepatic-pancreatic dysplasia, Joubert syndrome with renal defect, karyomegalic interstitial nephritis) show the same pattern: high scores, no clinical evidence and no plausible mechanism. The only partial exception is the theoretical symptomatic relief of movement abnormalities in some neurological conditions, which would not address the underlying disease.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available for the top-ranked predicted indication.

(For context, the only paper retrieved across the top 10 predictions, PMID 11293103, is a 2001 case report in Revista de Neurologia on spasmodic torticollis with vertebral haemangioma. It relates to thoracic malformation, the rank 5 prediction, and does not support tetrabenazine use there.)

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 1330B	iNova Pharmaceuticals (Australia) Pty Ltd	Tablet 25 mg (oral)	Not available in the data compiled for this report

Safety Considerations

Contraindication-related conditions (from the knowledge graph, not product label text): The knowledge graph links tetrabenazine with the following conditions, which warrant caution:

Cardiovascular: long QT syndrome (including familial), torsades de pointes, orthostatic hypotension, postural orthostatic tachycardia syndrome, hypotensive disorders, multiple system atrophy
Psychiatric: anxiety disorder, neurotic disorder, dysthymic disorder
Hepatobiliary: liver disease, gallbladder disease
Movement disorders: tardive dyskinesia, lingual-facial-buccal dyskinesia, parkinsonian disorder, Parkinson disease, drug-induced akathisia
Endocrine: hyperprolactinaemia (including familial and acquired forms) and prolactin-producing pituitary tumour

Drug Interactions: 100 interactions were recorded, of which 20 are listed in the data compiled for this report. Major-level interactions include:

Bupropion
Dolasetron
Metoclopramide

Moderate-level interactions include famotidine, loperamide, morphine, lorcaserin, clarithromycin, levofloxacin, palonosetron, dronabinol, nabilone, eliglustat, diphenoxylate, difenoxin and several bowel-preparation laxatives (bisacodyl, picosulfuric acid, sodium sulfate, polyethylene glycol with electrolytes). Metronidazole is a minor interaction. Several of these (for example dolasetron, clarithromycin, levofloxacin) are relevant to QT prolongation. The knowledge graph also lists long QT syndrome as a caution.

Please refer to the TGA-approved Product Information (PI) for official warnings and contraindications, as label-based safety text was not available.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests only on a network-based model score. There are no registered trials, no supportive literature and no plausible mechanistic link between VMAT2 inhibition and cystogenesis. The evidence level is L5.

To proceed, the following is needed:

Mechanistic data (original mode of action is currently unavailable) and a biological hypothesis connecting VMAT2 inhibition to the predicted disease
Preclinical evidence in relevant models of polycystic kidney or liver disease
TGA Product Information (warnings, contraindications and approved indication) to enable safety screening
A safety assessment covering QT prolongation, depression and suicidality, and hepatic and renal considerations in the target population
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.